Literature DB >> 23332729

CD8+ clonality is associated with prolonged acute plasma viremia and altered mRNA cytokine profiles during the course of feline immunodeficiency virus infection.

Michelle M Miller1, Elizabeth M Thompson, Steven E Suter, Jonathan E Fogle.   

Abstract

Acute lentiviral infection is characterized by early CD8(+) cytotoxic T cell (CTL) activity and a subsequent decline in plasma viremia. However, CD8(+) lymphocytes fail to eliminate the virus and a progressive T cell immune dysfunction develops during the course of chronic lentiviral infection. To further define this CD8(+) immune dysfunction we utilized PARR (PCR for antigen receptor rearrangements), a technique which measures clonally expanded lymphocyte populations by comparison of highly conserved T cell receptor (TCR) regions to identify the prevalence of clonal CD8(+) T cells following FIV infection. We then compared phenotype, mRNA profiles, CD8(+) proliferation and plasma viremia during acute and chronic infection for PARR positive (PARR(+)) and PARR negative (PARR(-)) Feline Immunodeficiency Virus (FIV) infected cats. We demonstrated that approximately forty percent of the FIV(+) cats examined exhibit CD8(+) clonality compared to none of the FIV(-) control cats. There were no phenotypic differences between PARR(+) and PARR(-) CD8(+) lymphocytes from FIV(+) cats but retrospective analysis of plasma viremia over the course of infection revealed a delayed peak in plasma viremia and a decline in lymphocyte counts were observed in the PARR(+) group during acute infection. CD8(+) lymphocytes isolated from chronically infected PARR(-) cats exhibited significantly higher mRNA expression of IFN-γ and IL-2 following mitogenic stimulation when compared to PARR(+) CD8(+) lymphocytes. These data suggest that clonal CD8(+) expansion may be related to impaired control of acute viremia and less effective CD8(+) anti-viral function. Using PARR to assess changes in CD8(+) clonality during the progression from acute to chronic FIV infection may help to better characterize the factors which contribute to CD8(+) anergy and lentiviral persistence.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23332729      PMCID: PMC3595358          DOI: 10.1016/j.vetimm.2012.12.005

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  40 in total

Review 1.  Effector and memory CTL differentiation.

Authors:  Matthew A Williams; Michael J Bevan
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 2.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection.

Authors:  Susan M Kaech; E John Wherry
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

3.  Interleukin-10 determines viral clearance or persistence in vivo.

Authors:  David G Brooks; Matthew J Trifilo; Kurt H Edelmann; Luc Teyton; Dorian B McGavern; Michael B A Oldstone
Journal:  Nat Med       Date:  2006-10-15       Impact factor: 53.440

4.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.

Authors:  D A Price; P J Goulder; P Klenerman; A K Sewell; P J Easterbrook; M Troop; C R Bangham; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

5.  HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory.

Authors:  E John Wherry; Cheryl L Day; Rika Draenert; Joseph D Miller; Photini Kiepiela; Tonia Woodberry; Christian Brander; Marylyn Addo; Paul Klenerman; Rafi Ahmed; Bruce D Walker
Journal:  Virology       Date:  2006-07-24       Impact factor: 3.616

6.  Progressive expansion of an L-selectin-negative CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats.

Authors:  D H Gebhard; J L Dow; T A Childers; J I Alvelo; M B Tompkins; W A Tompkins
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

7.  Characterization of C-, J- and V-region-genes of the feline T-cell receptor gamma.

Authors:  A Th A Weiss; W Hecht; M Henrich; M Reinacher
Journal:  Vet Immunol Immunopathol       Date:  2008-03-25       Impact factor: 2.046

8.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

9.  Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection.

Authors:  Julien van Grevenynghe; Francesco A Procopio; Zhong He; Nicolas Chomont; Catherine Riou; Yuwei Zhang; Sylvain Gimmig; Genevieve Boucher; Peter Wilkinson; Yu Shi; Bader Yassine-Diab; Elias A Said; Lydie Trautmann; Mohamed El Far; Robert S Balderas; Mohamed-Rachid Boulassel; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2008-03-02       Impact factor: 53.440

10.  Resolution of a chronic viral infection after interleukin-10 receptor blockade.

Authors:  Mette Ejrnaes; Christophe M Filippi; Marianne M Martinic; Eleanor M Ling; Lisa M Togher; Shane Crotty; Matthias G von Herrath
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

View more
  2 in total

1.  Modulating DNA methylation in activated CD8+ T cells inhibits regulatory T cell-induced binding of Foxp3 to the CD8+ T Cell IL-2 promoter.

Authors:  Michelle M Miller; Nnenna Akaronu; Elizabeth M Thompson; Sylvia F Hood; Jonathan E Fogle
Journal:  J Immunol       Date:  2014-12-29       Impact factor: 5.422

2.  Improved neurocognitive performance in FIV infected cats following treatment with the p75 neurotrophin receptor ligand LM11A-31.

Authors:  Jonathan E Fogle; Lola Hudson; Andrea Thomson; Barbara Sherman; Margaret Gruen; B Duncan Lacelles; Brenda M Colby; Gillian Clary; Frank Longo; Rick B Meeker
Journal:  J Neurovirol       Date:  2021-03-04       Impact factor: 3.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.